Literature DB >> 29622865

The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.

Mohamed A M Ali1, Emad K Ahmed1, Magda M A Assem2, Reham Helwa3.   

Abstract

Although the clinical features of isocitrate dehydrogenase (IDH) genetic aberrations have been well-characterized in acute myeloid leukemia (AML), definitive information on their prognostic significance is lacking. We aimed to explore the prognostic significance of IDH gene alterations in an Egyptian cohort of adult patients with de novo AML. Diagnostic peripheral blood samples from 51 AML patients were analyzed for the presence of mutations/SNPs in exon 4 of IDH1 and IDH2 genes using polymerase chain reaction amplification followed by direct sequencing. IDH mutational status had no impact on event-free survival (EFS) and overall survival (OS), whereas the presence of IDH1 315C>T SNP was significantly associated with inferior EFS (P = 0.037) and OS (P = 0.034) as compared with wild-type IDH1. IDH1 315C>T SNP but not IDH mutations is associated with unfavorable outcomes, suggesting that AML patients with IDH1 315C>T SNP can represent a new subgroup of patients which allows refined risk stratification.

Entities:  

Keywords:  Acute myeloid leukemia; Isocitrate dehydrogenase 1 and 2; Mutations; Prognostic markers; Single nucleotide polymorphisms

Year:  2017        PMID: 29622865      PMCID: PMC5884974          DOI: 10.1007/s12288-017-0852-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  30 in total

1.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Authors:  Katharina Wagner; Frederik Damm; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Oliver Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna A Raghavachar; Walter Fiedler; Hartmut H Kirchner; Wolfram Brugger; Manuela Zucknick; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

2.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

Review 3.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

Review 4.  Silent SNPs: impact on gene function and phenotype.

Authors:  Anton A Komar
Journal:  Pharmacogenomics       Date:  2007-08       Impact factor: 2.533

5.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

6.  Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.

Authors:  Jens Tiesmeier; Andreas Czwalinna; Carsten Müller-Tidow; Jürgen Krauter; Hubert Serve; Gerhard Heil; Arnold Ganser; Walter Verbeek
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

7.  Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.

Authors:  Roberta Leonardi; Chitra Subramanian; Suzanne Jackowski; Charles O Rock
Journal:  J Biol Chem       Date:  2012-03-22       Impact factor: 5.486

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

9.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Katharina Wagner; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna Raghavachar; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Michael Heuser; Jürgen Krauter; Arnold Ganser
Journal:  Blood       Date:  2010-04-26       Impact factor: 25.476

10.  Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Authors:  Nicolas Boissel; Olivier Nibourel; Aline Renneville; Claude Gardin; Oumedaly Reman; Nathalie Contentin; Dominique Bordessoule; Cécile Pautas; Thierry de Revel; Bruno Quesnel; Pascal Huchette; Nathalie Philippe; Sandrine Geffroy; Christine Terre; Xavier Thomas; Sylvie Castaigne; Hervé Dombret; Claude Preudhomme
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 50.717

View more
  2 in total

1.  Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.

Authors:  Elizabeth M Corley; Moaath K Mustafa Ali; Hanan Alharthy; Kathryn A F Kline; Danielle Sewell; Jennie Y Law; Seung Tae Lee; Sandrine Niyongere; Vu H Duong; Maria R Baer; Ashkan Emadi
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

2.  EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma.

Authors:  Mohiuddin M Taher; Ghida Dairi; Ejaz Muhammad Butt; Khalid Al-Quthami; Hisham Al-Khalidi; Raid A Jastania; Tahani H Nageeti; Neda M Bogari; Mohammad Athar; Faisal A Al-Allaf; Kristoffer Valerie
Journal:  Oncol Lett       Date:  2020-10-23       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.